Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LUNG NASDAQ:MDAI NASDAQ:PDEX OTCMKTS:VASO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLUNGPulmonx$1.60-0.3%$1.67$1.47▼$9.37$65.00M0.42431,440 shs43,055 shsMDAISpectral AI$2.25+0.4%$2.17$1.01▼$3.25$59.98M0.92543,439 shs253,504 shsPDEXPro-Dex$28.15+6.8%$36.48$23.47▼$70.26$92.25M-0.1148,292 shs34,205 shsVASOVaso$0.11-3.1%$0.12$0.11▼$0.17$19.41M1.3982,325 shs452 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLUNGPulmonx-0.62%-0.62%-13.04%-51.81%-73.90%MDAISpectral AI-6.67%-15.15%-4.68%-17.34%+56.64%PDEXPro-Dex+1.07%+4.94%-23.24%-47.09%-7.31%VASOVaso-1.04%-1.13%-5.56%-8.23%-28.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLUNGPulmonx$1.60-0.3%$1.67$1.47▼$9.37$65.00M0.42431,440 shs43,055 shsMDAISpectral AI$2.25+0.4%$2.17$1.01▼$3.25$59.98M0.92543,439 shs253,504 shsPDEXPro-Dex$28.15+6.8%$36.48$23.47▼$70.26$92.25M-0.1148,292 shs34,205 shsVASOVaso$0.11-3.1%$0.12$0.11▼$0.17$19.41M1.3982,325 shs452 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLUNGPulmonx-0.62%-0.62%-13.04%-51.81%-73.90%MDAISpectral AI-6.67%-15.15%-4.68%-17.34%+56.64%PDEXPro-Dex+1.07%+4.94%-23.24%-47.09%-7.31%VASOVaso-1.04%-1.13%-5.56%-8.23%-28.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLUNGPulmonx 2.40Hold$7.66380.52% UpsideMDAISpectral AI 2.00Hold$3.5055.62% UpsidePDEXPro-Dex 2.50Moderate Buy$56.0098.92% UpsideVASOVaso 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VASO, PDEX, MDAI, and LUNG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025LUNGPulmonxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MDAISpectral AIWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PDEXPro-DexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/27/2025LUNGPulmonxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MDAISpectral AIWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PDEXPro-DexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/8/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.008/1/2025LUNGPulmonxWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$6.00 ➝ $3.007/31/2025LUNGPulmonxLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.007/31/2025LUNGPulmonxStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $5.007/31/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $16.00(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLUNGPulmonx$83.79M0.78N/AN/A$2.17 per share0.74MDAISpectral AI$29.58M2.03N/AN/A($0.32) per share-7.03PDEXPro-Dex$66.59M1.39$3.38 per share8.32$11.23 per share2.51VASOVaso$83.05M0.23$0.01 per share11.37$0.16 per share0.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLUNGPulmonx-$56.39M-$1.43N/AN/AN/A-62.88%-69.76%-36.26%10/29/2025 (Estimated)MDAISpectral AI-$15.31M-$0.69N/AN/AN/A-51.97%N/A-8.69%11/5/2025 (Estimated)PDEXPro-Dex$8.98M$2.7010.4213.67N/A13.48%26.67%14.95%10/30/2025 (Estimated)VASOVaso$950K-$0.01N/A∞N/A-0.35%-1.14%-0.38%11/12/2025 (Estimated)Latest VASO, PDEX, MDAI, and LUNG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025MDAISpectral AI-$0.08N/AN/AN/A$5.06 millionN/A10/30/2025Q1 2026PDEXPro-Dex$0.50N/AN/AN/A$15.30 millionN/A10/29/2025Q3 2025LUNGPulmonx-$0.40N/AN/AN/A$20.78 millionN/A9/4/2025Q4 2025PDEXPro-Dex$0.47$0.36-$0.11$0.36$17.90 million$17.49 million8/12/2025Q2 2025MDAISpectral AI-$0.07-$0.10-$0.03-$0.31$5.44 million$5.07 million7/30/2025Q2 2025LUNGPulmonx-$0.40-$0.38+$0.02-$0.38$23.46 million$23.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLUNGPulmonxN/AN/AN/AN/AN/AMDAISpectral AIN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/AVASOVasoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLUNGPulmonx0.545.354.63MDAISpectral AIN/A0.870.84PDEXPro-Dex0.253.231.71VASOVasoN/A1.511.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLUNGPulmonx91.04%MDAISpectral AI67.08%PDEXPro-Dex15.28%VASOVasoN/AInsider OwnershipCompanyInsider OwnershipLUNGPulmonx6.80%MDAISpectral AI30.70%PDEXPro-Dex45.90%VASOVaso44.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLUNGPulmonx25040.75 million37.98 millionOptionableMDAISpectral AI8326.73 million18.53 millionNot OptionablePDEXPro-Dex1403.28 million1.77 millionNot OptionableVASOVaso260175.95 million97.65 millionNot OptionableVASO, PDEX, MDAI, and LUNG HeadlinesRecent News About These CompaniesSickle Cell Drug Suspension Confirmed by EMAOctober 17, 2025 | medscape.comMVASO by Eco Launches Collaborative Net Zero Project to Develop Heat Pump Solution for Buildings in Towns and CitiesOctober 15, 2025 | msn.comSmall Business: Turning grief into art with handcrafted urn business VasoOctober 12, 2025 | nzherald.co.nzNBlood-Based Protein Biomarkers Linked to Acute Pain in Sickle Cell DiseaseOctober 10, 2025 | clinicalpainadvisor.comCHigh-Resolution 7-Tesla MRI Reveals Brain Microvessel Pulsations Linked to Aging: StudyOctober 8, 2025 | medicaldialogues.inMIndividuals with sickle cell disease face long delays to pain care in emergency departmentOctober 8, 2025 | msn.comGene-Edited Cells Alleviate Pain Crisis in Sickle Cell DiseaseSeptember 18, 2025 | medscape.comMTelescope Innovations Appoints Vaso Vlachos as Chief Operating OfficerSeptember 2, 2025 | finance.yahoo.comBKFC Budva live results: Vaso Bakocevic faces Wilhelm OttAugust 30, 2025 | fightmag.comFVASO Central Bank Of India IFSC Code, KHEDAAugust 26, 2025 | moneycontrol.comVaso Stock Down Following Q2 Earnings as Revenue and Margins FallAugust 21, 2025 | zacks.comPfizer Provides Update on Phase 3 Inclacumab Study for the Treatment of People with Sickle Cell DiseaseAugust 19, 2025 | pipelinereview.comPInclacumab Misses Endpoint In Sickle Cell Disease TrialAugust 19, 2025 | empr.comEPfizer's sickle cell drug fails late-stage trialAugust 15, 2025 | msn.comPfizer's sickle-cell treatment efforts falter as drug fails studyAugust 15, 2025 | msn.comVaso Corporation reports Q2 revenue $20M vs. $20.2M last yearAugust 14, 2025 | msn.comVaso Corporation Announces Financial Results for Second Quarter of 2025August 14, 2025 | finance.yahoo.comVaso Corporation Announces Financial Results for Second Quarter of 2025 | VASO Stock NewsAugust 14, 2025 | gurufocus.comFirst Patient Dosed In Clinical Trial Of Therapy For Sickle DiseaseAugust 8, 2025 | msn.comGreece stuns USA to reach women’s water polo World Championship finalJuly 23, 2025 | neoskosmos.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVASO, PDEX, MDAI, and LUNG Company DescriptionsPulmonx NASDAQ:LUNG$1.60 -0.01 (-0.31%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Spectral AI NASDAQ:MDAI$2.25 +0.01 (+0.40%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.Pro-Dex NASDAQ:PDEX$28.15 +1.79 (+6.80%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Vaso OTCMKTS:VASO$0.11 0.00 (-3.08%) As of 09:48 AM EasternVaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
